RT Journal Article
SR Electronic
T1 Biotransformation of 5-(2-chloroethyl)-2'-deoxyuridine in male NMRI mice.
JF Drug Metabolism and Disposition
JO Drug Metab Dispos
FD American Society for Pharmacology and Experimental Therapeutics
SP 683
OP 689
VO 17
IS 6
A1 I Szinai
A1 E de Clercq
YR 1989
UL http://dmd.aspetjournals.org/content/17/6/683.abstract
AB When the selective anti-herpes agent [2-14C]-5-(2-chloroethyl)-2'-deoxyuridine [( 14C]CEDU) was administered as a single oral dose to mice, 87.9% of the radioactivity was excreted in the urine and 11.2% in the feces within 72 hr. Compounds accounting for 84% of the 14C radioactivity in the 0- to 24-hr urine were isolated by various chromatographic techniques and identified by MS, NMR, IR, and CD analysis. Approximately 25% of the radioactivity found in the urine was the parent compound (CEDU). According to the 14C-metabolites detected in the urine, one may infer that [14C]CEDU is metabolized, first, by cleavage of its N-glycosidic bond, resulting in the formation of 5-(2-chloroethyl)uracil (38.7%) and, second, by stereoselective hydroxylation of the alpha carbon atom of the haloalkyl side chain of 5-(2-chloroethyl)uracil, resulting in the formation of 5-(1-hydroxy-2-chloroethyl)uracil (29.6%). CEDU was absorbed rapidly from the gastrointestinal tract and the bloodstream, and did not show any particular accumulation in mouse tissues, as revealed by whole body autoradiography.